Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Sales | 5,102,000 | 5,676,000 | 4,344,000 | 4,212,000 | 4,080,000 |
| Cost of Goods | 2,493,000 | 2,795,000 | 2,098,000 | 2,012,000 | 1,892,000 |
| Gross Profit | 2,609,000 | 2,881,000 | 2,246,000 | 2,200,000 | 2,188,000 |
| Operating Expenses | 1,681,000 | 1,841,000 | 1,211,000 | 1,603,000 | 1,321,000 |
| Operating Income | 928,000 | 1,040,000 | 1,035,000 | 597,000 | 867,000 |
| Other Income | -82,000 | -517,000 | -84,000 | 10,000 | -53,000 |
| Pre-tax Income | 846,000 | 523,000 | 951,000 | 607,000 | 814,000 |
| Income Tax | -9,000 | 18,000 | 33,000 | 27,000 | 49,000 |
| Net Income Continuous | 855,000 | 505,000 | 918,000 | 580,000 | 765,000 |
| Minority Interests | -4,000 | -1,000 | 2,000 | 4,000 | 4,000 |
| Net Income | $859,000 | $506,000 | $916,000 | $576,000 | $761,000 |
| EPS Basic Total Ops | 0.98 | 0.57 | 1.03 | 0.65 | 0.85 |
| EPS Basic Continuous Ops | 0.97 | 0.57 | 1.03 | 0.65 | 0.85 |
| EPS Diluted Total Ops | 0.97 | 0.58 | 1.03 | 0.64 | 0.84 |
| EPS Diluted Continuous Ops | 0.97 | 0.57 | 1.03 | 0.65 | 0.85 |
| EBITDA(a) | $1,447,000 | $1,372,000 | $1,282,000 | $821,000 | $1,133,000 |